
News|Videos|April 17, 2026
Industry Report: Advanced Therapy Market May Triple by 2030
Author(s)Fran Gregory, PharmD, Stephen Appezzato
Fran Gregory, VP of Emerging Therapies at Cardinal Health, discusses key findings from the company's 2026 Advanced Therapy Report.
Advertisement
Advertisement
A new industry report signals a pivotal shift in the delivery of life-altering treatments.1 As the market for cell and gene therapies grows, there is increasing industry support to move away from the highly centralized access model of academic medical centers toward a decentralized, community-based approach. Drawing on insights from 160 physicians and administrators, Cardinal Health’s 2026 Advanced Therapy Report details how this shift is a clinical necessity driven by a rapidly expanding therapy pipeline.1
Related to this article

At LogiPharma USA 2026, Cold Chain Technologies' Anthony "TJ" Rizzo discusses cold chain expertise gaps and how data tools are reshaping the profession.

Zoomlogi's Henry Ames explains how AI agents and digitized SOPs help quality managers decide on quarantine or release after a cold chain excursion.

Epic's Prescription Marketplace, due summer 2027, will show pharmacy cash prices next to insured costs before a prescription is sent.

At LogiPharma USA 2026, Cold Chain Technologies' Vijay Paliwal explains how predictive monitoring and right-sized packaging cut excursion risk and waste.

Zoomlogi’s Henry Ames says exception handling still hinges on experienced staff, and AI agents could gather and document details for their judgment calls.

At LogiPharma USA 2026, BMS’s Kevin Cook explains why CMO partnerships must move beyond transactions toward shared goals and KPIs.

In this week's Pharma Pulse, DHL adds six dedicated cold chain air corridors linking Europe and North America to Asia, Walmart rolls out a $0 prescription tier and rare disease Center of Excellence for its US workforce and FDA launches its Rare Disease Framework Initiative.
Advertisement
Advertisement

